D. Ford, D. F. Easton, and D. T. Bishop, Risks of cancer in BRCA1-mutation carriers, Breast Cancer Linkage Consortium. Lancet, vol.343, pp.692-695, 1994.

D. Ford, D. F. Easton, and M. Stratton, Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium, Am J Hum Genet, vol.62, pp.676-689, 1998.

S. V. Tavtigian, J. Simard, and J. Rommens, The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds, Nat Genet, vol.12, pp.333-337, 1996.

R. Wooster, G. Bignell, and J. Lancaster, Identification of the breast cancer susceptibility gene BRCA2, Nature, vol.378, pp.789-792, 1995.

K. B. Kuchenbaecker, J. L. Hopper, and D. R. Barnes, Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers, JAMA, vol.317, pp.2402-2416, 2017.

D. Eccles, A. Marlow, and G. Royle, Genetic epidemiology of early onset breast cancer, Journal of Medical Genetics, vol.31, pp.944-949, 1994.

J. F. Stratton, D. Thompson, and L. Bobrow, The genetic epidemiology of early-onset epithelial ovarian cancer: a population-based study, Am J Hum Genet, vol.65, pp.1725-1732, 1999.

D. F. Easton, D. Ford, and D. T. Bishop, Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium, Am J Hum Genet, vol.56, pp.265-271, 1995.

A. Antoniou, P. Pharoah, and S. Narod, Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies, Am J Hum Genet, vol.72, pp.1117-1130, 2003.

, Thésaurus -Femmes porteuses d'une mutation de BRCA1 ou BRCA2 / Détection précoce du cancer du sein et des annexes et stratégies de réduction du risque, Collection recommandations et référentiels, p.2017

S. Chen and G. Parmigiani, Meta-analysis of BRCA1 and BRCA2 penetrance, J Clin Oncol, vol.25, pp.1329-1333, 2007.

M. B. Daly, R. Pilarski, and J. E. Axilbund, Genetic/familial high-risk assessment: breast and ovarian, J Natl Compr Canc Netw, vol.12, pp.1326-1338, 2014.

S. Paluch-shimon, F. Cardoso, and C. Sessa, Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening, Ann Oncol, vol.27, pp.103-110, 2016.

, Tools and resources | Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer | Guidance | NICE

M. Tilanus-linthorst, H. F. Lingsma, G. Evans, and D. , Optimal age to start preventive measures in women withBRCA1/2mutations or high familial breast cancer risk, International Journal of Cancer, vol.133, pp.156-163, 2013.

J. Semple, K. A. Metcalfe, and J. Lubinski, Does the age of breast cancer diagnosis in first-degree relatives impact on the risk of breast cancer in BRCA1 and BRCA2 mutation carriers?, Breast Cancer Res Treat, vol.154, pp.163-169, 2015.

K. Metcalfe, J. Lubinski, and H. T. Lynch, Family History of Cancer and Cancer Risks in Women with BRCA1 or BRCA2 Mutations, JNCI Journal of the National Cancer Institute, vol.102, pp.1874-1878, 2010.

C. B. Begg, R. W. Haile, and Å. Borg, Variation of Breast Cancer Risk Among BRCA1/2 Carriers, JAMA, vol.299, 2008.

S. A. Narod, Modifiers of risk of hereditary breast cancer, Oncogene, vol.25, pp.5832-5836, 2006.

O. M. Sinilnikova, A. C. Antoniou, and A. B. Spurdle, Common breast cancer predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers, European Journal of Cancer Supplements, vol.6, pp.207-208, 2008.

R. L. Milne and A. C. Antoniou, Genetic modifiers of cancer risk for BRCA1 and BRCA2 mutation carriers, Annals of Oncology, vol.22, pp.11-17, 2011.

T. M. Friebel, S. M. Domchek, and T. R. Rebbeck, Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysis, J Natl Cancer Inst, vol.106, p.91, 2014.

F. Lesueur, N. Mebirouk, and Y. Jiao, GEMO, a National Resource to Study Genetic Modifiers of Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Pathogenic Variant Carriers, Frontiers in Oncology, vol.8, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01926758

D. Thompson and D. Easton, Breast Cancer Linkage Consortium (2002) Variation in BRCA1 cancer risks by mutation position, Cancer Epidemiol Biomarkers Prev, vol.11, pp.329-336

D. Thompson and D. F. Easton, Cancer Incidence in BRCA1 Mutation Carriers, Obstetrical & Gynecological Survey, vol.58, pp.27-28, 2003.

T. R. Rebbeck, M. N. Wan, and F. , Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer, JAMA, vol.313, pp.1347-1361, 2015.

D. Thompson and D. Easton, Breast Cancer Linkage Consortium (2001) Variation in cancer risks, by mutation position, in BRCA2 mutation carriers, Am J Hum Genet, vol.68, pp.410-419

N. Mavaddat, S. Peock, and D. Frost, Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE, J Natl Cancer Inst, vol.105, pp.812-822, 2013.

P. Pujol, D. S. Lyonnet, and T. Frebourg, Lack of referral for genetic counseling and testing in BRCA1/2 and Lynch syndromes: a nationwide study based on 240,134 consultations and 134,652 genetic tests, Breast Cancer Res Treat, vol.141, pp.135-144, 2013.
URL : https://hal.archives-ouvertes.fr/hal-02282713

A. M. Gonzalez-angulo, K. M. Timms, and S. Liu, Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer, Clin Cancer Res, vol.17, pp.1082-1089, 2011.

M. Hubalek, T. Czech, and H. Müller, Biological Subtypes of Triple-Negative Breast Cancer. Breast Care, vol.12, pp.8-14, 2017.

J. D. Fackenthal and O. I. Olopade, Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations, Nat Rev Cancer, vol.7, pp.937-948, 2007.

N. M. Tun, G. Villani, and K. Ong, Risk of having BRCA1 mutation in high-risk women with triple-negative breast cancer: a meta-analysis, Clin Genet, vol.85, pp.43-48, 2014.

F. Podo, F. Santoro, D. Leo, and G. , Triple-Negative versus Non-Triple-Negative Breast Cancers in High-Risk Women: Phenotype Features and Survival from the HIBCRIT-1 MRI-Including Screening Study, Clin Cancer Res, vol.22, pp.895-904, 2016.

B. E. Dogan and L. W. Turnbull, Imaging of triple-negative breast cancer, Ann Oncol, vol.23, pp.23-32, 2012.

W. D. Foulkes, I. E. Smith, and J. S. Reis-filho, Triple-negative breast cancer, N Engl J Med, vol.363, pp.1938-1948, 2010.
URL : https://hal.archives-ouvertes.fr/hal-02463255

S. J. Dawson, E. Provenzano, and C. Caldas, Triple negative breast cancers: Clinical and prognostic implications, European Journal of Cancer, vol.45, pp.27-40, 2009.

R. Dent, M. Trudeau, and K. I. Pritchard, Triple-negative breast cancer: clinical features and patterns of recurrence, Clin Cancer Res, vol.13, pp.4429-4434, 2007.

S. Noda, N. Onoda, and T. Morisaki, The significance and the predictive factors of microscopic lymph node metastasis in patients with clinically node negative papillary thyroid cancer: A retrospective cohort study, International Journal of Surgery, vol.20, pp.52-57, 2015.

X. Phi, N. Houssami, and I. Obdeijn, Magnetic Resonance Imaging Improves Breast Screening Sensitivity in BRCA Mutation Carriers Age ? 50 Years: Evidence From an Individual Patient Data Meta-Analysis, Journal of Clinical Oncology, vol.33, pp.349-356, 2015.

X. Phi, S. Saadatmand, D. Bock, and G. H. , Contribution of mammography to MRI screening in BRCA mutation carriers by BRCA status and age: individual patient data metaanalysis, Br J Cancer, vol.114, pp.631-637, 2016.

C. C. Riedl, N. Luft, and C. Bernhart, Triple-modality screening trial for familial breast cancer underlines the importance of magnetic resonance imaging and questions the role of mammography and ultrasound regardless of patient mutation status, age, and breast density, J Clin Oncol, vol.33, pp.1128-1135, 2015.

K. Metcalfe, A. Eisen, and L. Senter, International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation, Br J Cancer, 2019.

C. Julian-reynier, J. Mancini, and E. Mouret-fourme, Cancer risk management strategies and perceptions of unaffected women 5 years after predictive genetic testing for BRCA1/2 mutations, Eur J Hum Genet, vol.19, pp.500-506, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00697966

K. A. Metcalfe, D. Birenbaum-carmeli, and J. Lubinski, International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers, International Journal of Cancer, vol.122, pp.2017-2022, 2008.

G. H. De-bock, K. M. Vermeulen, and L. Jansen, Which screening strategy should be offered to women with BRCA1 or BRCA2 mutations? A simulation of comparative costeffectiveness, Br J Cancer, vol.108, pp.1579-1586, 2013.

R. Pataky, L. Armstrong, and S. Chia, Cost-effectiveness of MRI for breast cancer screening in BRCA1/2 mutation carriers, BMC Cancer, vol.13, p.339, 2013.

L. Petelin, A. H. Trainer, and G. Mitchell, Cost-effectiveness and comparative effectiveness of cancer risk management strategies in BRCA1/2 mutation carriers: a systematic review, Genet Med, vol.20, pp.1145-1156, 2018.

A. Finch, J. Lubinski, and P. Møller, Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation, J Clin Oncol, vol.32, pp.1547-1553, 2014.

A. Podfigurna-stopa, A. Czyzyk, and M. Grymowicz, Premature ovarian insufficiency: the context of long-term effects, J Endocrinol Invest, vol.39, pp.983-990, 2016.

S. M. Domchek, T. M. Friebel, and C. F. Singer, Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality, JAMA, vol.304, pp.967-975, 2010.

C. Marchetti, F. De-felice, and I. Palaia, Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers, BMC Womens Health, vol.14, p.150, 2014.

T. R. Rebbeck, N. D. Kauff, and S. M. Domchek, Meta-analysis of Risk Reduction Estimates Associated With Risk-Reducing Salpingo-oophorectomy in BRCA1 or BRCA2 Mutation Carriers, JNCI Journal of the National Cancer Institute, vol.101, pp.80-87, 2009.

C. F. Singer, M. K. Tea, and G. Pristauz, Clinical Practice Guideline for the prevention and early detection of breast and ovarian cancer in women from HBOC (hereditary breast and ovarian cancer) families, Wiener klinische Wochenschrift, vol.127, pp.981-986, 2015.

J. Mancini, E. Mouret-fourme, C. Noguès, and C. Julian-reynier, Impact of BRCA1/2 mutation on young women's 5-year parenthood rates: a prospective comparative study (GENEPSO-PS cohort), Familial Cancer, vol.14, pp.273-279, 2015.
URL : https://hal.archives-ouvertes.fr/inserm-01991277

J. Chan, L. N. Johnson, and L. Digiovanni, Reproductive decision-making in patients diagnosed with BRCA mutations, Fertility and Sterility, vol.104, p.76, 2015.

F. A. Peccatori, G. Mangili, and A. Bergamini, Fertility preservation in women harboring deleterious BRCA mutations: ready for prime time?, Hum Reprod, vol.33, pp.181-187, 2018.

J. Kim, M. D. Gammon, C. Skrzynia, and J. E. Mersereau, BRCA mutation carriers: a new target population for fertility preservation consultation and treatment, Fertility and Sterility, vol.100, p.190, 2013.

V. Gunnala, J. Fields, and M. Irani, BRCA carriers have similar reproductive potential at baseline to noncarriers: comparisons in cancer and cancer-free cohorts undergoing fertility preservation, Fertil Steril, vol.111, pp.363-371, 2019.

M. Grynberg, J. Raad, and M. Comtet, Fertility preservation in BRCA-mutated women: when and how?, Future Oncol, vol.14, pp.483-490, 2018.

R. L. Milne and A. C. Antoniou, Modifiers of breast and ovarian cancer risks for BRCA1 and BRCA2 mutation carriers, Endocr Relat Cancer, vol.23, pp.69-84, 2016.

A. Osorio, R. L. Milne, and G. Pita, Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA), Br J Cancer, vol.101, pp.2048-2054, 2009.

A. M. Mulligan, F. J. Couch, and D. Barrowdale, Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2, Breast Cancer Res, vol.13, p.110, 2011.
URL : https://hal.archives-ouvertes.fr/inserm-00670601

A. C. Antoniou, C. Kartsonaki, and O. M. Sinilnikova, Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers, Hum Mol Genet, vol.20, pp.3304-3321, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00771696

H. Bugrein, Genotype and phenotype correlation of breast cancer in BRCA carriers and non-carriers, Journal of Cancer Science & Therapy, p.7, 2015.

S. M. Bujassoum, H. A. Bugrein, and A. Sulaiman, Genotype and Phenotype Correlation of Breast Cancer in BRCA Mutation Carriers and Non-Carriers, Journal of Cancer Science & Therapy, p.9, 2017.

J. Lecarpentier, C. Noguès, and E. Mouret-fourme, Breast Cancer Risk Associated with Estrogen Exposure and Truncating Mutation Location in BRCA1/2 Carriers, Cancer Epidemiol Biomarkers Prev, vol.24, pp.698-707, 2015.
URL : https://hal.archives-ouvertes.fr/inserm-01990932

N. Andrieu, D. F. Easton, and J. Chang-claude, Effect of chest X-rays on the risk of breast cancer among BRCA1/2 mutation carriers in the international BRCA1/2 carrier cohort study: a report from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS Collaborators' Group, J Clin Oncol, vol.24, pp.3361-3366, 2006.

A. George, S. Kaye, and S. Banerjee, Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer, Nat Rev Clin Oncol, vol.14, pp.284-296, 2017.

U. S. , Breast Cancer Statistics | Breastcancer.org. In: Breastcancer.org, 2019.

, Institut National Du Cancer Epidémiologie des cancers -Les chiffres du cancer en France, Accessed, vol.11, 2019.

N. Pearce, Classification of epidemiological study designs, International Journal of Epidemiology, vol.41, pp.393-397, 2012.

P. H. Kass, Modern Epidemiological Study Designs. Handbook of Epidemiology, pp.325-363, 2014.

, de mes chers condisciples et devant l'effigie d'Hippocrate, je promets et je jure d'être fidèle aux lois de l'honneur et de la probité dans l'exercice de la médecine

, Je donnerai mes soins gratuits à l'indigent et n'exigerai jamais un salaire au-dessus de mon travail

, Admise dans l'intérieur des maisons, mes yeux ne verront pas ce qui s'y passe, ma langue taira les secrets qui me seront confiés, et mon état ne servira pas à corrompre les moeurs

, Respectueuse et reconnaissante envers mes Maîtres, je rendrai à leurs enfants l'instruction que j'ai reçue de leurs pères

, Que les Hommes m'accordent leur estime si je suis fidèle à mes promesses. Que je sois couverte d'opprobre et méprisée de mes confrères si j'y manque

, Cette étude visait à évaluer la prévalence cumulée des CTP du sein et des ovaires chez les femmes BRCA1/2. Les objectifs secondaires étaient d'évaluer l'association entre la survenue d'un CUP chez une femme BRCA1/2 et l'âge de survenue des cancers du sein ou des ovaires chez ses apparentées et d'analyser la corrélation génotype-phénotype. Nous avons mené une étude rétrospective monocentrique consécutive colligeant les données oncologiques personnelles et familiales de tous les patients porteurs d'une mutation BRCA1/2 dans l'unité d'oncogénétique du CHU de Montpellier de, Résumé Les estimations de la fréquence de survenue des cancers très précoces (CTP) du sein (avant 30 ans) et des ovaires (avant 40 ans) chez les femmes porteuses d'une mutation germinale dans les gènes BRCA1/2 (femmes BRCA1/2) sont imprécises et non concordantes dans la littérature, pp.37-40, 2003.

, Mots-clés Cancer du sein

, Very-early-onset (VEO) breast (under 30) and ovarian (under 40) cancers estimates in women carrying a germline mutation in BRCA1 or BRCA2 (BRCA1/2 women) are inaccurate and inconsistent. This study aimed to measure VEO breast and ovarian cancers cumulative prevalence in BRCA1/2 women. We secondarily aimed to assess the relationship between VEO cancer in BRCA1/2 women and ages at breast and ovarian cancer diagnosis in their relatives, and to seek for phenotype-genotype correlations. We conducted a retrosepctive consecutive single-center study, collecting personal and family cancer data of all BRCA1/2 patients referred to Cancer Genetics Departement of CHU Montpellier from, p.448, 2003.

, BRCA1/2 families, including 78 (17%) families with at least one VEO breast or ovarian cancer. Cumulative prevalence of VEO breast cancer was 5, vol.09, p.95

, There was no significant relationship between VEO cancer occurrence and ages at cancer diagnosis within the family. VEO breast cancer frequency in BRCA1/2 women could prompt to implement MRI screening from age 25, BRCA1 and BRCA2 respectively, p.73